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Abstract
Background and Objectives. Several studies of autologus stem cell transplant in primary refractory myeloma reported encouraging results. However, the outcome of primary refractory patients with stable disease has not been analized separately from that of those with progressive disease.
Design and Methods. In the Spanish Myeloma Group 2000 trial, 80 primary refractory patients (49 stable and 31 progressive) to the initial chemotherapy were scheduled to tandem transplant (double autologous or single followed by allogeneic transplantation). Primary refractory disease includes patients who never achieved minimal response (≥25% M-protein decrease) or better.
Response was assessed by the European Bone Marrow Transplant criteria.
Results. There were no significant differences in partial response or better between patients with stable or progressive disease. However, 38% of stable patients remained with stable condition or achieved minimal response after transplantation versus 7% in the progressive group (p=0.0017) and early progression after transplantation was significantly higher among the progressive group (22% vs 2%, p=0.0043). After a median follow-up of 6.6 years, the median survival of the whole series after first transplant was 2.3 years.
Progression-free and overall survival from the first transplant were shorter in patients with progressive disease (0.6 vs 2.3 years, p=0.00004 and 1.1 vs. 6 years, p=0.00002, respectively).
Conclusions.
Our results show that patients with progressive refractory myeloma do not benefit from autologous transplant, while patients with stable disease have an outcome comparable to those with chemosensitive disease. 
INTRODUCTION
The outcome of patients with multiple myeloma (MM) treated with conventional therapy is unsatisfactory with a low proportion of long-term survivors. For this reason, high-dose therapy followed by autologous stem cell transplantation (ASCT) has become the standard of care in the up-front therapy in younger patients with MM [1] [2] [3] [4] . In fact, it has been shown that the survival of patients younger than 60 years has improved in the more recent years and this has been attributed, at least in part, to the benefit of ASCT [5] [6] [7] .
Before the introduction of novel drugs, particularly thalidomide, bortezomib and lenalidomide, the pretransplant induction therapy consisted of alkylator and/or dexamethasone-based regimens. With these regimens, the pretransplant CR rate ranged from 5-10% and increased up to 35% after transplant [1] [2] [8] [9] [10] . In fact, the benefit of ASCT in terms of survival was attributed to the higher frequency of CR obtained after the intensive therapy 1,2 . In addition, tandem autologous has shown to be of benefit for patients failing to achieve at least very good partial response (VGPR) with the first transplant [11] [12] .
Whether ASCT is beneficial for the majority of patients or the overall benefit comes from certain subsets of patients is still an unsolved issue 4, 13 . In this regard, it has been claimed that patients with primary resistant disease are the most likely to benefit from early ASCT 14, 15 . However, there is a paucity of published evidence to support this practice [15] [16] [17] [18] [19] [20] This study allowed the recognition of two populations of refractory myeloma patients with different outcome.
DESIGN AND METHODS
Study design
Patients diagnosed with symptomatic MM between October 1, 1999 and Declaration of Helsinki. The study was registered at ClinicalTrials.gov identified as NCT00560053.
High-dose therapy
Peripheral blood stem cell (PBSC) collection was performed after cycle 4 using granulocyte colony-stimulating factor ( 
Response criteria
Response, relapse and progression were assessed according to European
Bone Marrow Transplant (EBMT) criteria 24 . Complete response (CR) was defined as negative immunofixation in serum and urine, <5% plasma cells in a bone marrow aspirate as well as disappearance of soft tissue plasmacytomas and no increase in lytic bone lesions. Partial response (PR) was defined as a decrease of serum M-protein in ≥50% and 24 hours urinary ligh-chain excretion by ≥ 90% or to <200 mg and reduction of extramedullary plasmacytomas in protein between 25-49% and 50-89% reduction in 24 hours urine light-chain protein excretion. Responses should be maintained for a minimum of 6 weeks.
Relapse from CR was defined as reappearance of serum or urinary paraprotein on immunofixation, development of new extramedullary plasmacytomas, increase in size or developing of new lytic lesions or hypercalcemia.
Progressive disease required an increase in serum M-protein by >25% with an absolute increase of at least 5 g/L or increase in urine M-protein by >25% and also an absolute increase ≥ 200 mg/24h, and/or the appearance of soft-tissue plasmacytomas, new lytic bone lesions or hypercalcemia.
Criteria for primary refractory disease
Primary refractory disease includes patients who never achieve MR or better in whom there is no significant change in M protein and have no evidence of clinical progression (no change or nonresponsive, non-progressive, stable disease -SD-), as well as primary refractory progressive disease patients who meet criteria for true progressive disease (serum and/or urine M-protein increase ≥ 25% and/or developing increasing skeletal involvement, anemia, plasmacytomas or hypercalcemia while on the initial chemotherapy) 21 (progressive disease -PD-)
Statistical Methods
The χ 2 test or the Fisher's exact test were used when required to assess the statistical significance of multiple comparisons. The Kaplan-Meier method was used to plot the survival curves, which were compared by the log-rank test 25 .
RESULTS
Eighty patients with primary refractory myeloma (48M, 32F, median age 56 yrs)
were included in this study. Among the 80 patients, 49 were classified as stable disease (SD-refractory patients) whereas the remaining 27 had progressive disease (PD-refractory patients) while on treatment. Four additional patients who achieved a very transient partial response (PR) when they were receiving the initial chemotherapy but showed a rapid progression before transplant were included in the subgroup of PD-refractory patients. The prognostic features, were similar in both subgroups of refractory patients (SD vs. PD). The initial characteristics of the patients are shown in Table 1 .
Response to first autologous transplant
Twenty-seven patients received BUMEL as conditioning regimen and 53 MEL-200. Overall, 69% of the patients responded to the first ASCT (CR: 4%, PR: 51%, MR: 14%). Nine (12%) patients remained with stable disease after the procedure and eight (10%) had progressive disease after HDT. Transplantrelated mortality (TRM) was 9% with no significant differences between SD and PD patients (6% vs. 13%). There were no significant differences in response rate (CR+PR) between the two subgroups of refractory patients (54% vs. 58%
in patients with SD and PD, respectively). However, 38% of patients with SD at transplant remained with stable condition or achieved a minimal response after transplant versus only 7% in the PD patients (p=0.0017). Moreover, early progression within the first three months after HDT was significantly higher among the PD-refractory patients as compared the SD-refractory patients (22.5% vs. 2%, p=0.0043). The response rates after the first ASCT is summarized in Table 2 .
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Flow-chart of patients undergoing a second transplant
Although refractory patients were scheduled to receive a tandem transplant (double auto or auto followed by Allo-RIC), fourty did not undergo the second high-dose procedure. The reasons for not proceeding with the second transplant were: death (n=8), poor performance status (8), PD (7) 
Response to second transplant
Response rates after the second transplant are detailed in Table 3 . Only 11%
and 33% of patients achieved CR after tandem ASCT and Allo-RIC, respectively. TRM was 7% vs. 11% with the second ASCT and the allo-RIC groups, respectively.
Survival
After a median follow-up for alive patients of 6.6 years, the median survival of the whole series after the first transplant was 2. shorter overall survival from the first transplant than that of the SD group (median 1.1 vs. 6 years, p=0.00002) (Figure 2 ).
DISCUSSION
Autologous stem-cell transplant is considered the standard of care in younger patients with newly diagnosed symptomatic MM [1] [2] [3] [4] . The beneficial effect of the ASCT likely results from the higher tumor reduction attained as compared to that achieved with conventional chemotherapy (i.e. CR 40% vs. less than 10%) 20, 26, 27 . Therefore, the identification of factors that can predict a CR achievement is important to limit ASCT to those patients most likely to benefit from the procedure. In our experience 28 and in that of Alexanian et al 26 , the tumor burden, measured by the serum and urine M-protein size at the time of transplant, is the most important predictor of CR postransplant 26, 28 .
Patients with primary resistant disease have a poor prognosis with standard chemotherapy, with a median OS between 1.5 and 3 years 15, 29 . It has been suggested that these patients are the most likely to benefit from ASCT provided that the rescue transplant is performed early in the course of the disease before the emergence of resistant clones. In six published series, the reported CR rate was between 8-40% and the OS ranged from 4 to 6 years [15] [16] [17] [18] [19] . Thus, in a series from the M. D. Anderson 15 , the median EFS and OS of 27 patients with primary resistant disease who received a transplant during the first year from initiation of therapy were 3.5 and 6 years, respectively. In addition, in one study from the University of Arkansas 16 , the median EFS and OS in 72 patients with primary unresponsive disease were 21 and 47 months, respectively. In a study of the Royal Marsden, a 40% CR rate after transplant was reported in a series of 43 primary refractory patients. In this series, the CR was only assessed by In our study, patients with primary refractory disease had a poor prognosis with a median PFS of 1.2 yrs and OS of 2.3 yrs. This could be explained by the low CR rate achieved after transplant (5% after first ASCT, 11% after double autologous and 33% after tandem auto/allo-RIC). Moreover, differences among our results and those reported in the other series could be due to several reasons. First, criteria used to define "primary refractory disease" have been different. Thus, in our study, only patients with stable disease or progressive disease as defined in the EBMT 24 criteria have been included. In contrast, in the previous series patients failing to achieve a MR 15, 20, 26 or even a PR 18, 19 according to the EBMT criteria were considered to have primary refractory disease. Second, in all the other series the primary therapy was mainly steroidbased while our patients had received combination chemotherapy mainly based on alkylating agents, steroids and doxorubicin. Finally, the two categories of patients considered as primary refractory disease (ie, primary unresponsive with progressive disease vs. no change without clinical progression) should be analyzed separately 21 . Thus, in our series, PD-refractory patients had an extremely poor prognosis, with a median PFS and OS of only 7 and 13 months postransplant, respectively. In contrast, SD-refractory patients had a PFS of 27 months and a median OS of 73 months after a median of follow-up of 6.6 years, which is similar to that reported in chemosensitive patients 30 . It is of note that although the achievement of at least PR after the first ASCT was similar in the two subgroups of patients (54% vs. 58%) the duration of response was very limited in the PD group. In addition, 38% of the nonresponding/nonprogressive group achieved MR or remained with stable disease while almost one-fourth of patients with unresponsive progressive disease while on initial chemotherapy showed progressive disease after the first transplant. In contrast, Singhal et al
In the era of new drugs, a high overall response rate and CR rate pretransplant is achieved [31] [32] [33] . However, the issue of primary refractory disease is not yet solved and thus our analysis is relevant today. In fact, in the current Spanish trial, comparing 4 cycles of VBMCP/VBAD plus 2 cycles of bortezomib vs. 6
cycles of thalidomide/dexamethasone (TD) vs. 6 cycles of bortezomib, thalidomide, dexamethasone(VTD) the progressive disease is as high as 12%, 23% and 7%, respectively 34 . Although whether or not patients refractory to novel agents will benefit from ASCT is not yet known it would be reasonable to offer these patients salvage regimens or experimental therapies to significantly decrease the tumor burden before transplant, which is the crucial factor associated with complete response after transplant which is the main surrogate for a prolonged survival.
In summary, our results show that patients with unresponsive progressive disease do not benefit from ASCT. In consequence, novel treatment approaches, including experimental drugs, should be offered to these patients.
In contrast, patients with non-responding non-progressive disease have a good outcome with an overall survival comparable to those with chemosensitive disease. However, whether this is due to the benefit of high-dose therapy or to the natural history of a more indolent disease is uncertain.
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